Conventional bulk RNA sequencing homogenizes millions of cells, producing an averaged gene expression profile that completely masks rare cell subtypes, transitional cellular states, and critical spatial interactions within heterogeneous tissues. The convergence of **Single-Cell RNA Sequencing (scRNA-seq)** and **Spatial Transcriptomics** provides unprecedented single-cell resolution, allowing computational biologists to deconstruct the complex architecture of the tumor microenvironment (TME) and identify novel therapeutic drug targets.
1. Droplet-Based Single-Cell Sequencing Workflow (10x Genomics Chromium)
Modern high-throughput scRNA-seq relies on droplet-based microfluidics:
- Single-Cell Encapsulation: Individual cells are partitioned into nanoliter oil droplets alongside a hydrogel bead coated with barcoded oligonucleotides.
- Unique Molecular Identifiers (UMIs): Each bead contains millions of oligonucleotides with a shared Cell Barcode (identifying the cell) and a unique UMI (counting individual mRNA transcripts to eliminate PCR amplification bias).
- Reverse Transcription & In-Drop Lysis: Cells are lysed inside the droplet, where the poly(A) tails of released mRNAs hybridize to the oligo(dT) primers on the bead for cDNA synthesis.
2. Preserving the Tissue Matrix: Spatial Transcriptomics Platforms
While scRNA-seq provides deep single-cell transcriptomes, tissue dissociation destroys anatomical and spatial context. Spatial transcriptomics platforms (such as 10x Visium, MERFISH, and CosMx Spatial Molecular Imager) capture gene expression directly on intact formalin-fixed paraffin-embedded (FFPE) histological tissue sections.
By registering transcriptomic data directly onto high-resolution H&E pathology images, oncologists can map how immunosuppressive tumor-associated macrophages (TAMs) physically exclude cytotoxic T-cells from the tumor core, uncovering critical paracrine resistance mechanisms.